Scott B. Willoughby's most recent trade in Sangamo Therapeutics Inc was a trade of 31,866 Common Stock done at an average price of $0.5 . Disclosure was reported to the exchange on July 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, CHIEF LEGAL OFFICER, SECY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.48 per share. | 22 Jul 2025 | 31,866 | 749,677 (0%) | 0% | 0.5 | 15,289 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, CHIEF LEGAL OFFICER, SECY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 24 May 2025 | 1,433 | 781,543 (0%) | 0% | 0.5 | 678 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.78 per share. | 22 Apr 2025 | 31,866 | 782,976 (0%) | 0% | 0.8 | 24,738 | Common Stock |
| Sangamo Therapeutics Inc | Willoughby Scott B. | SVP, GEN. COUNSEL & SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 560,000 | 560,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | B. Scott Willoughby | SVP, GEN. COUNSEL & SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 120,000 | 814,842 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | B. Scott Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.00 per share. | 24 Feb 2025 | 1,434 | 696,217 (0%) | 0% | 1 | 1,434 | Common Stock |
| Sangamo Therapeutics Inc | B. Scott Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.96 per share. | 24 Feb 2025 | 1,375 | 694,842 (0%) | 0% | 1.0 | 1,315 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 22 Jan 2025 | 129,549 | 697,651 (0%) | 0% | 1.1 | 148,981 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.88 per share. | 24 Nov 2024 | 1,430 | 828,571 (0%) | 0% | 1.9 | 2,688 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.94 per share. | 24 Nov 2024 | 1,371 | 827,200 (0%) | 0% | 1.9 | 2,660 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 24 Aug 2024 | 1,430 | 831,372 (0%) | 0% | 0.9 | 1,230 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 24 Aug 2024 | 1,371 | 830,001 (0%) | 0% | 0.9 | 1,179 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.98 per share. | 13 Aug 2024 | 892 | 832,802 (0%) | 0% | 1.0 | 870 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.60 per share. | 24 May 2024 | 1,400 | 835,030 (0%) | 0% | 0.6 | 840 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.60 per share. | 24 May 2024 | 1,336 | 833,694 (0%) | 0% | 0.6 | 802 | Common Stock |
| Sangamo Therapeutics Inc | B. Willoughby Scott | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 24 Feb 2024 | 4,379 | 839,883 (0%) | 0% | 1.1 | 4,948 | Common Stock |
| Sangamo Therapeutics Inc | B. Scott Willoughby | SVP, GEN. COUNSEL & SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 24 Feb 2024 | 3,453 | 836,430 (0%) | 0% | 1.1 | 3,902 | Common Stock |
| Sangamo Therapeutics Inc | Willoughby Scott B. | SVP, GEN. COUNSEL & SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 712,500 | 844,262 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.77 per share. | 25 Aug 2023 | 1,329 | 128,091 (0%) | 0% | 0.8 | 1,023 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.08 per share. | 13 Aug 2023 | 864 | 129,420 (0%) | 0% | 1.1 | 933 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.33 per share. | 25 May 2023 | 1,328 | 125,284 (0%) | 0% | 1.3 | 1,766 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.65 per share. | 24 Apr 2023 | 3,977 | 126,612 (0%) | 0% | 1.6 | 6,562 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 199,500 | 199,500 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 42,750 | 135,717 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 24 Feb 2023 | 5,128 | 130,589 (0%) | 0% | 2.7 | 13,640 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.33 per share. | 13 Aug 2022 | 864 | 92,966 (0%) | 0% | 6.3 | 5,469 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.15 per share. | 29 Apr 2022 | 140 | 90,709 (0%) | 0% | 4.2 | 581 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.70 per share. | 24 Apr 2022 | 3,976 | 90,849 (0%) | 0% | 4.7 | 18,687 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 110,700 | 110,700 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 41,000 | 94,825 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.90 per share. | 25 Feb 2022 | 1,566 | 53,825 (0%) | 0% | 5.9 | 9,239 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.12 per share. | 29 Oct 2021 | 140 | 54,455 (0%) | 0% | 8.1 | 1,137 | Common Stock |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Scott B. Willoughby | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 7,500 | 54,595 (0%) | 0% | 0 | Common Stock |